Gennova Bio gets US drug patent to treat brain clots
MUMBAI: Decks have been cleared for a more affordable stroke treatment — developed by domestic company Gennova Biopharmaceuticals — to go global. The Pune-based biotech company has been granted a…
USD 550 million awarded in lawsuit linking cancer, baby powder
R St Louis (US): Nearly two dozen women who claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer were awarded USD 550 million in damages by a…
Lupin, Boehringer Ingelheim to co-market two oral anti-diabetic drugs in India
New Delhi: Drug major Lupin Wednesday said it has expanded its collaboration with Germany’s Boehringer Ingelheim for co-marketing two oral anti-diabetic drugs in India. The two new oral anti-diabetics drugs…
Religare Finvest claims Rs 1,900 crore from 19 companies ‘known to’ Malvinder and Shivinder Singh
NEW DELHI: Religare Finvest, the lending arm of Religare Enterprises, has filed claims totalling Rs 1,900 crore against 19 companies that were linked to its former promoters Malvinder and Shivinder…
Sun Pharma’s subsidiary files patent infringement suit against German drug maker Biofrontera
Sun pharma’s US subsidiary DUSA pharmaceuticals on Wednesday said that the company has filed a law suit against German drug maker Biofrontera for patent infringement, trade secret misappropriation and tortious…
Glenmark expands its oncology franchise in India with launch of Helsinn’s Akynzeo
New Delhi, Jul 10 : Glenmark Pharmaceuticals and Swiss pharma group Helsinn today announced the launch of Akynzeo, a fixed dose combination drug for prevention of chemotherapy-induced nausea and vomiting,…
Sun Pharma signs Akshay Kumar as brand ambassador for Revital H
New Delhi: Sun Pharma signs Akshay Kumar as brand ambassador for Revital H Drug major Sun Pharmaceutical Industries Monday said Sun Pharma Consumer Healthcare has signed Bollywood star Akshay Kumar…
Aurobindo in last lap to buy Mallinckrodt’s US generics business
MUMBAI: Aurobindo Pharma is in final negotiations to acquire Mallinckrodt’s specialty generics business in the US—including its portfolio of opioid-based painkillers—for $850-900 million after talks resumed in May, said multiple…
Firms marketing medicines may soon be liable for drug regulation violations
CHENNAI: Companies marketing medicines in India will soon be liable for violations of drug regulations that could lead to spurious or substandard medicines even if they aren’t manufacturers of these…
TPG to acquire 40% in Sai Life for Rs 900 crore
Mumbai: TPG has pipped rival private equity investors to acquire a stake of slightly over 40% in Sai Life Sciences — a Hyderabad-based provider of drug discovery, development and manufacturing…
